Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
+0.53 (1.43%)
After Hours: 37.20 0.00 (0.00%)
Oct 24, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.10 - 37.72
52 week 33.16 - 110.75
Open 36.85
Vol / Avg. 1.11M/1.78M
Mkt cap 3.19B
P/E     -
Div/yield     -
EPS -4.24
Shares 85.72M
Beta 2.51
Inst. own 88%
Nov 7, 2016
Q3 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 11, 2016
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-HBV for the treatment of hepatitis B virus (HBV) infection - Webcast
Oct 5, 2016
Alnylam Pharmaceuticals Inc Discontinues Revusiran Development - Webcast
Sep 28, 2016
Alnylam Pharmaceuticals Inc at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
Sep 27, 2016
Alnylam Pharmaceuticals Inc Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1 - Webcast
Sep 16, 2016
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
Sep 14, 2016
Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference
Sep 13, 2016
2016 RNAi Roundtable: ALN-AS1 for the Treatment of Acute Hepatic Porphyrias Call
Aug 31, 2016
2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases Call - Webcast
Aug 22, 2016
2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders Corporate Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1034.89% -705.83%
Operating margin -1061.55% -720.27%
EBITD margin - -673.91%
Return on average assets -26.79% -23.52%
Return on average equity -31.61% -26.36%
Employees 369 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
David-Alexandre Gros M.D. Principal Financial Officer, Chief Business Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Yvonne Greenstreet Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D. Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
.. Bartlett Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Michael P. Mason Principal Accounting Officer, Vice President, Treasurer
Age: 41
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters